![]() Currently, there are 97.02 million shares of Fate Therapeutics Inc stock available for purchase. ![]() The AAII Stock Evaluator puts a company’s grades, charts, news, financials, valuation, ratios, filings and more at your fingertips.įate Therapeutics Inc’s Stock Price as of Market CloseĪs of February 17, 2023, 4:00 PM CST, Fate Therapeutics Inc’s stock price was $6.55.įate Therapeutics Inc is up 6.68% from its previous closing price of $6.14.ĭuring the last market session, Fate Therapeutics Inc’s stock traded between $6.12 and $6.39. Want to learn more about Fate Therapeutics Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Fate Therapeutics Inc. FT596 is an investigational off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal engineered master iPSC line. FT516 is an investigational off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel CD16 (hnCD16) Fc receptor. The Company is advancing a pipeline of programmed cellular immunotherapies, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master iPSC lines for the treatment of cancer. It uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer. is a clinical-stage biopharmaceutical company.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |